PL2124977T3 - Sposób leczenia lub zapobiegania ogólnoustrojowemu stanowi zapalnemu - Google Patents

Sposób leczenia lub zapobiegania ogólnoustrojowemu stanowi zapalnemu

Info

Publication number
PL2124977T3
PL2124977T3 PL08730501T PL08730501T PL2124977T3 PL 2124977 T3 PL2124977 T3 PL 2124977T3 PL 08730501 T PL08730501 T PL 08730501T PL 08730501 T PL08730501 T PL 08730501T PL 2124977 T3 PL2124977 T3 PL 2124977T3
Authority
PL
Poland
Prior art keywords
treating
systemic inflammation
preventing systemic
preventing
infant
Prior art date
Application number
PL08730501T
Other languages
English (en)
Inventor
Robert J Mcmahon
William Michael Russell
Udo Herz
Josef Neu
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39469924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2124977(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of PL2124977T3 publication Critical patent/PL2124977T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08730501T 2007-02-28 2008-02-22 Sposób leczenia lub zapobiegania ogólnoustrojowemu stanowi zapalnemu PL2124977T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90412207P 2007-02-28 2007-02-28
EP08730501A EP2124977B9 (en) 2007-02-28 2008-02-22 Method for treating or preventing systemic inflammation
PCT/US2008/054710 WO2008106372A1 (en) 2007-02-28 2008-02-22 Method for treating or preventing systemic inflammation

Publications (1)

Publication Number Publication Date
PL2124977T3 true PL2124977T3 (pl) 2012-07-31

Family

ID=39469924

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08730508T PL2114423T3 (pl) 2007-02-28 2008-02-22 Produkt zawierający unieczynniony probiotyk dla niemowląt
PL08730501T PL2124977T3 (pl) 2007-02-28 2008-02-22 Sposób leczenia lub zapobiegania ogólnoustrojowemu stanowi zapalnemu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08730508T PL2114423T3 (pl) 2007-02-28 2008-02-22 Produkt zawierający unieczynniony probiotyk dla niemowląt

Country Status (13)

Country Link
US (2) US9408818B2 (pl)
EP (2) EP2114423B2 (pl)
CN (3) CN105796607A (pl)
AT (1) ATE544457T1 (pl)
BR (2) BRPI0808145A2 (pl)
CA (2) CA2679374C (pl)
ES (2) ES2388198T5 (pl)
MX (2) MX2009009119A (pl)
MY (2) MY151892A (pl)
PL (2) PL2114423T3 (pl)
RU (2) RU2468807C2 (pl)
TW (2) TWI494114B (pl)
WO (2) WO2008106373A1 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2008106373A1 (en) * 2007-02-28 2008-09-04 Mead Johnson Nutrition Company Product containing inactivated probiotic for children or infants
AU2008333718B2 (en) * 2007-12-06 2012-03-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage
CA2742476A1 (en) * 2008-11-03 2010-06-03 Nestec S.A. A nutritional composition comprising probiotics and improving sleep patterns
US8568743B2 (en) * 2009-04-29 2013-10-29 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
EP2251022A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Non-replicating micro-organisms and their immune boosting effect
US8784798B2 (en) * 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
BR112012017978A2 (pt) * 2010-01-19 2016-05-03 Abbott Lab fórmulas nutricionais contendo simbióticos
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
EP2455093A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2455094A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect children against gastrointestinal infections
CN103209596A (zh) * 2010-11-11 2013-07-17 雀巢产品技术援助有限公司 含有益生微生物的冷冻糖食
EP2452576A1 (en) * 2010-11-11 2012-05-16 Nestec S.A. Extruded non-replicating probiotic micro-organisms and their health benefits
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR101166798B1 (ko) * 2011-12-19 2012-07-26 김대현 락토바실러스 애시도필러스 엘비의 사균을 포함하는 알레르기 질환의 치료 또는 예방용 의약 조성물
WO2013103826A1 (en) * 2012-01-06 2013-07-11 Skyview Enterprise Ltd. Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation
US20130251829A1 (en) * 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10265351B2 (en) * 2013-08-09 2019-04-23 Ab-Biotics, S.A. Probiotic for infantile colic
WO2015082151A1 (en) * 2013-11-25 2015-06-11 Nestec S.A. Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations
CN106231924A (zh) * 2013-11-29 2016-12-14 雀巢产品技术援助有限公司 按年龄定制的具有不同蛋白质含量的营养组合物
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ME03511B (me) 2015-06-15 2020-04-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
ES2657665B1 (es) * 2016-09-05 2018-12-17 Pedro Jose DE LA FUENTE BLASCO Productos para la salud con probióticos inactivados y uso de dichos productos
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107115362A (zh) * 2017-04-28 2017-09-01 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗支气管哮喘制剂中的应用
ES2877726T3 (es) 2017-05-22 2021-11-17 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
CN108041607A (zh) * 2017-12-26 2018-05-18 广州普正生物科技有限公司 一种护齿益生菌咀嚼软胶囊
RU2770463C1 (ru) * 2020-10-14 2022-04-18 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный технический университет им. И.И. Ползунова" (АлтГТУ) Способ производства мягкого сыра
TWI802009B (zh) * 2021-09-16 2023-05-11 創百股份有限公司 使用熱致死的乳酸菌菌株來治療和/或預防微粒物質-誘發的肺損傷
EP4712990A1 (en) 2023-05-15 2026-03-25 BactoPharma GmbH Treatment of cancer therapy-induced oral mucositis
EP4569082A2 (en) 2023-10-09 2025-06-18 Science Power Srl Methods of preparing a postbiotic composition

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804179A (en) 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
US6156320A (en) * 1993-02-05 2000-12-05 Harry Parsekian Fermented milk nutraceuticals
RU2031586C1 (ru) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
US6180100B1 (en) 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
EP0965643B1 (en) 1998-06-17 2003-11-05 Societe Des Produits Nestle S.A. Mobile genetic elements as tools for genetic modification of L. delbrueckii or L. helveticus
US6399055B1 (en) 1998-10-27 2002-06-04 Compagnie Gervais Danone Method and composition for treatment of infant diarrhea
EP1137423B1 (en) 1998-12-11 2005-03-09 Urex Biotech, Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
AU2001233529A1 (en) * 2000-02-10 2001-08-20 Andrew W. Bruce Probiotic therapy for newborns
NZ526443A (en) 2000-12-18 2005-03-24 Probiohealth Llc Probiotic compounds derived from lactobacillus casei strain KE01
KR100419132B1 (ko) 2000-12-29 2004-02-18 조성근 위·장 점막 부착성과 증식성, 내산성, 내담즙성 및헬리코박터 파일로리, 대장균 0157:ｈ7에 대한 항균성이우수한 락토바실러스 파라카제이 서브스패시즈 파라카제이ｃｓｋ 01
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
KR100845456B1 (ko) 2001-02-06 2008-07-10 소시에떼 데 프로듀이 네슬레 소시에떼아노님 젖산균 및 비피도균에 의한 내독소 결합
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
PE20030283A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
PE20030274A1 (es) 2001-07-26 2003-05-08 Alimentary Health Ltd Cepas de lactobacillus salivarius
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
US20050100531A1 (en) 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
SI1565547T2 (sl) 2002-06-28 2013-02-28 Biosearch S.A. Probiotiäśni sevi, postopek za izbiranje le-teh, njihovi sestavki in njihova uporaba
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
WO2004069156A2 (en) 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
EP1608383A1 (en) 2003-03-31 2005-12-28 Alimentary Health Limited A formulation comprising a bacterial strain
RU2346449C2 (ru) 2003-06-23 2009-02-20 Нестек С.А. Смесь для детей первых месяцев жизни или старше
WO2005085287A1 (en) 2004-03-03 2005-09-15 En-N-Tech, Inc. Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
EP1725662A4 (en) * 2004-03-15 2008-03-05 Tissugen Pty Ltd INFECTIOUS ETHIOLOGY OF A PROSTATE INFECTION AND METHOD OF IDENTIFYING CAUSE OF INJURY
AU2006235307B2 (en) 2005-04-08 2011-07-14 Alimentary Health Ltd Methods of use of orally administered probiotic Bifidobacteria for human beauty benefits
WO2006108824A1 (en) 2005-04-13 2006-10-19 Nestec S.A. Infant formula with probiotics
US20060233752A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
WO2006124630A2 (en) * 2005-05-13 2006-11-23 New England Medical Center Hospitals, Inc. Compositions and methods for enhancing the efficacy of vaccines
WO2008106373A1 (en) * 2007-02-28 2008-09-04 Mead Johnson Nutrition Company Product containing inactivated probiotic for children or infants

Also Published As

Publication number Publication date
CA2679374C (en) 2016-05-31
EP2124977B1 (en) 2012-02-08
RU2009135871A (ru) 2011-04-10
CN101678053B (zh) 2015-12-16
HK1136969A1 (en) 2010-07-16
BRPI0808145A2 (pt) 2021-03-23
TWI494114B (zh) 2015-08-01
US9408819B2 (en) 2016-08-09
EP2114423A1 (en) 2009-11-11
CA2676956C (en) 2017-06-13
TWI418355B (zh) 2013-12-11
MX2009008875A (es) 2009-08-28
CN101678053A (zh) 2010-03-24
RU2009135873A (ru) 2011-04-10
WO2008106372A1 (en) 2008-09-04
EP2114423B2 (en) 2020-01-01
ATE544457T1 (de) 2012-02-15
TW200906426A (en) 2009-02-16
ES2381232T3 (es) 2012-05-24
CN105796607A (zh) 2016-07-27
EP2124977B9 (en) 2012-05-02
BRPI0808052A2 (pt) 2014-06-24
WO2008106373A1 (en) 2008-09-04
CA2676956A1 (en) 2008-09-04
HK1141729A1 (zh) 2010-11-19
RU2468808C2 (ru) 2012-12-10
MY145769A (en) 2012-04-13
CA2679374A1 (en) 2008-09-04
CN101636172A (zh) 2010-01-27
RU2468807C2 (ru) 2012-12-10
US20080206212A1 (en) 2008-08-28
TW200900075A (en) 2009-01-01
ES2388198T5 (es) 2020-07-14
PL2114423T3 (pl) 2012-10-31
MX2009009119A (es) 2009-09-04
EP2114423B1 (en) 2012-06-06
US20080206213A1 (en) 2008-08-28
MY151892A (en) 2014-07-14
EP2124977A1 (en) 2009-12-02
ES2388198T3 (es) 2012-10-10
US9408818B2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
PL2124977T3 (pl) Sposób leczenia lub zapobiegania ogólnoustrojowemu stanowi zapalnemu
PH12014501749A1 (en) A nutritional composition comprising probiotics and improving sleep patterns
TW200507766A (en) Nutritional composition
MY145410A (en) Method for preventing or treating respiratory infections and acute otitis media in infants
UA100985C2 (ru) Композиция для питания с нежизнеспособной бифидобактерией и неусваиваемым олигосахаридом
MX2009009931A (es) Probioticos para reducir el desarrollo de alergia en lactantes nacidos por cesarea.
EP2081523A4 (en) DEVICES, SYSTEMS AND METHODS FOR MAGNETIC FUEL SYSTEMS WHICH INFLUENCE THE TONGUE OR TONGUE CLINIC IN THE UPPER AIRWAYS
MX2011012063A (es) Formula alimenticia para bebes y niños pequeños que comprenden probioticos para bebes y niños pequeños.
UA96984C2 (en) Reduction of risk diarrhoea
PL1675546T3 (pl) Butelka, a zwłaszcza butelka dla niemowląt, jak również metoda jej produkcji
MX2010005132A (es) Uso de oligosacaridos conteniendo n-acetilactosamina para maduración de las respuestas inmunes en neonatos.
PL1761245T3 (pl) Naturalny ekstrakt zawierający ksantohumol, oraz sposób jego produkcji i wytworzone z niego produkty
CA120261S (en) Bottle
WO2008042101A3 (en) Probiotics for use in reducing the incidence and duration of illness
MX2010002978A (es) Formulacion nutritiva con alto contenido energetico.
PT1782818E (pt) Composição farmacêutica que compreende bacillus coagulans e simeticone para o tratamento de patologias gastrointestinais
AU302434S (en) Vibroheat capsule I
AP2009005098A0 (en) Ready-to-use therapeutic food (RUTF) product for treating severe acute malnutrition in children aged6-12 months and 1-3 years
Chantalakhana Contribution of water buffaloes in rural development
AU307784S (en) Infant safety harness
CA121718S (en) Package for enteral food
AU315762S (en) Exercise apparatus
UA52520U (ru) Способ лечения нарушений функционального состояния кишечника у новорожденных и детей младенческого возраста
UA36886U (ru) Способ получения сушенного мясного продукта
CA116344S (en) Container for chewing gum